Morning Overview on MSN
FDA-cleared tools speed lung cancer diagnosis and make treatment safer
Two FDA-cleared technologies are now available to speed the detection of suspicious lung nodules and reduce the physical ...
CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual ...
-- Milestone marks first of multiple planned diagnostic product launches on NGS roadmap -- Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in vitro ...
The clinical laboratory generates immense amounts of data each day that characterizes both healthy and abnormal, or disease, states. This data is so vast it can be overwhelming for individuals to ...
OraSure Technologies acquires Sherlock Biosciences to enhance its diagnostic test portfolio, targeting sexually transmitted infections with rapid self-testing solutions. OraSure Technologies, Inc. has ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced the presentation of a new scientific poster ...
Butterfly Network's CMUT technology could be a game-changer in ultrasound machines. GE HealthCare Technologies is trading at ...
Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...
Milestone marks first of multiple planned diagnostic product launches on NGS roadmap Powered by the Archer platform technology, IDT empowers molecular pathology laboratories with first in vitro ...
IDT announces the launch of Archer FUSIONPlex™-HT Dx and VARIANTPlex™-HT Dx in vitro diagnostic (IVD) offerings. "At IDT, we believe that precision diagnostics should be as reliable as they are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results